Hematological Neoplasms

Breyanzi is developed and produced by the global biopharmaceutical company manufacturer is Bristol Myers Squibb (BMS).

Breyanzi (lisocabtagene maraleucel; liso-cel) is a CD19-targeted CAR-T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of CAR-T cells.

On May 15th, 2024 (local time), the U.S. Food and Drug Administration (FDA) announced the accelerated approval of Breyanzi (lisocabtagene maraleucel), Bristol Myers Squibb’s CAR-T therapy, for an expanded indication to treat adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.

According to a retrospective study presented at the 2024 Transplantation & Cellular Therapy Meetings, a single infusion of brexucabtagene autoleucel (brexu-cel) achieved a higher rate of central nervous system (CNS) remission in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and active CNS involvement.

The American Association for Cancer Research (AACR) Annual Meeting is the most influential oncology scientific event globally. From population science and prevention, to cancer biology, translational medicine, and clinical research, to survivorship and advocacy, the AACR Annual Meeting showcases the outstanding achievements of cancer research institutions worldwide.

CD19 CAR-T cell therapy has significantly improved the prognosis of patients with relapsed/refractory large B-cell lymphoma (r/r LBCL), including diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and LBCL transformed from follicular lymphoma (t-FL) or non-follicular lymphoma (t-NFL).

Kymriah is a CD19-directed genetically modified autologous T-cell immunocellular therapy, in which the CD19 chimeric antigen receptor (CAR) is fixed on the T-cells.

Breyanzi (Lisocabtagene Maraleucel) is a CAR-T therapy developed by the global biopharmaceutical company Bristol Myers Squibb (BMS).

On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Brexucabtagene Autoleucel (Tecartus), a CD19-directed, genetically modified autologous T-cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Axicabtagene Ciloleucel (Yescarta) is a personalized immunocellular therapy that modifies a patient’s own T cells to fight cancer cells.